Full-Time
Develops gene therapies for rare diseases
No salary listed
No H1B Sponsorship
Cambridge, MA, USA
Hybrid
Hybrid work requires on-site attendance at a Sarepta facility in the United States and/or attendance at company-sponsored in-person events from time to time.
Bachelor's
See people who can refer or advise you
Sarepta Therapeutics focuses on developing precision genetic medicines to treat rare diseases. It specializes in Duchenne muscular dystrophy (DMD) and is advancing gene therapies for limb-girdle muscular dystrophy (LGMD), Charcot-Marie-Tooth disease, MPS IIIA, and other CNS disorders. The company conducts research and development, carries therapies through clinical trials, and seeks regulatory approvals to bring treatments to patients, earning revenue from approved therapies and strategic partnerships. Its goal is to speed up drug development from lab research to patient treatment and to build the world’s largest gene therapy manufacturing capacity to meet global demand.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
1980
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Wellness Program
Legend Biotech's CEO Ying Huang resigned abruptly on 24 July, with the company stating his departure was not due to any disagreement. Alan Bash, president of Legend's Carvykti Business Unit, will serve as interim CEO whilst a search for a permanent replacement is underway. Separately, Sarepta Therapeutics appointed Michael Severino as its new CEO following a five-month search. Severino, formerly president of AbbVie and CEO of Tessera Therapeutics, brings over 25 years of biopharma experience. He replaces Doug Ingram, who announced his retirement in February for personal reasons. The leadership changes come as Legend faces competition for its blockbuster CAR-T therapy Carvykti, whilst Sarepta recently implemented a 36% workforce reduction amid challenges with its DMD gene therapy Elevidys.
Sarepta Therapeutics has appointed Michael Severino as chief executive officer, effective 28 July 2026. Severino, who will also join the board of directors, brings over 25 years of biopharmaceutical experience to the Cambridge-based precision genetic medicine company. Severino previously served as CEO of Tessera Therapeutics and held senior positions at AbbVie, where he was vice chairman and president responsible for research and development. At AbbVie, he oversaw pipeline expansion and contributed to more than a dozen approved therapies. He succeeds Doug Ingram, who is retiring after leading Sarepta through significant growth, including approvals of two exon-skipping treatments and the first one-time gene therapy for Duchenne muscular dystrophy. Ingram will serve in an advisory capacity until the end of 2026.
Sarepta Therapeutics announced the FDA has accepted supplemental New Drug Applications to convert accelerated approvals for Duchenne muscular dystrophy therapies AMONDYS 45 and VYONDYS 53 to traditional approvals. The PDUFA action date is set for 28 February 2027. The applications are supported by the ESSENCE confirmatory study and real-world evidence from over 1,800 treated patients. This could strengthen the regulatory foundation of Sarepta's exon-skipping franchise. The development may help diversify Sarepta's regulatory position in DMD treatment, potentially offsetting concentration risk around its ELEVIDYS therapy. ELEVIDYS recently received an FDA boxed warning for acute liver injury in November 2025. Sarepta's narrative projects $1.4 billion revenue and $87.3 million earnings by 2029, requiring a 13.3% yearly revenue decline from current levels.
Sarepta Therapeutics reported statutory profits that disappointed investors, with underlying concerns emerging from the earnings analysis. The company increased its share count by 7.4% over the past year, diluting per-share returns despite generating net income. The biotechnology firm was unprofitable three years ago and last year, making year-on-year growth comparisons difficult. Whilst the company achieved profit over the last 12 months, earnings per share would have been stronger without the share dilution. Additionally, Sarepta's profit received a significant boost from unusual items worth $52 million in the last 12 months. These one-off contributions may make statutory profit a poor indicator of underlying earnings power. The combination of share dilution and unusual items raises questions about the sustainability of the company's reported profitability.
Sarepta Therapeutics reported Q1 2026 revenue of $730.8 million, down 1.9% year-over-year, but exceeding the consensus estimate of $467.85 million by 56.2%. The biotechnology company posted earnings per share of $3.16, compared to a loss of $3.42 in the prior-year quarter, surpassing the consensus estimate of $0.90 by 253%. Product revenue totalled $330.52 million, slightly above analyst estimates of $325.88 million, representing a 46% year-over-year decline. PMO Products generated $228.55 million, whilst ELEVIDYS contributed $101.97 million, exceeding expectations despite a 72.8% year-over-year decrease. Shares have fallen 5.6% over the past month. The stock currently holds a Zacks Rank of Hold.